

MECHANISM OF COMMON SYSTEMIC IMMUNODEFICIENCY DISORDERS

Running Title: A review on the mechanism of common systemic Immunodeficiency disorders

Abstract

A heterogeneous group of disorders with defects in at least one segment of the immune system. Immunodeficiency disorders could experience the ill effects of an assortment of clinical signs, including intermittent, extreme, or irregular diseases, autoimmunity, and lymphoproliferative/malignancies. Immunodeficiency involves an enormous amount of sicknesses, influencing the advancement of the immune system, its function, or both. Although the number of patients determined to have immunodeficiency is developing. However, numerous patients are diagnosed late; numerous cases experience the ill effects of difficulties by chronic infections, end-organ damage, or even demise before the diagnosis is made. Ideal determination and suitable treatment stay the keys to the successful management of patients. This review is to overview the various systemic immunodeficiency disorders and their mechanism of occurrence of immunodeficiency.

Keywords: Immunodeficiency, systemic, HIV, Diabetes Mellitus, Anemia

Introduction

An immune disorder characterized with the aid of recurrent infections and low antibody levels, mainly in immunoglobulins like IgG, IgM, and IgA (1). Immunodeficiency results from the absence of components of the immune system, including lymphocytes, phagocytes, and complement framework. These immunodeficiencies can be either primary, like Bruton illness, or secondary, as the one brought about by HIV infection (2)(3). Deletions in genes that encode cell surface proteins and cytokine receptors, such as CD19, CD20, CD21, and CD80, can be mostly a cause (4). Treatment choices are limited, and commonly involves lifelong immunoglobulin replacement therapy (5,6). The most common systemic immunodeficiency disorders are HIV, anemia, diabetes mellitus, chemotherapy-induced immunodeficiency disorders. Our team has extensive knowledge and research experience that has translate into high quality publications (7) (8)(9)(10)(11) (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)

Etiology

Immunodeficiency disorders can result from Prolonged (constant) and in addition to serious disorders like diabetes or cancer, drugs. Rarely, radiation treatment. Immunodeficiency disorders may result from practically any prolonged serious disorder. For instance, diabetes can bring about an immunodeficiency issue since white platelets don't work well when the glucose level is high (22). Human immunodeficiency infection (HIV) contamination brings about (AIDS), the most well-known serious procured immunodeficiency disorder. Many kinds of diseases can cause an immunodeficiency problem. For instance, any malignancy that influences the bone marrow (like leukemia and lymphoma) can keep the bone marrow from creating ordinary white platelets (B cells and T cells), which are essential for the immune system (23).

Mechanism of immunodeficiency disorders

Mechanism of HIV

HIV virion enters macrophages and CD4+ Lymphocytes by the adsorption of glycoproteins on its surface to receptors on the target cell followed by a combination of the viral envelope with the objective cell layer and the arrival of the HIV capsid into the cell (24)(25). HIV can likewise scatter by direct transmission starting with one cell then onto the next by a cycle of cell-to-cell spread, for which two pathways have been depicted. Right off the bat, a contaminated Lymphocyte can communicate infection straightforwardly to an Immune system microorganism utilizing a virological synapse (26)(27). Also, an antigen-presenting cell (APC), like a macrophage or dendritic cell, can send HIV to Lymphocytes by a cycle that either includes productive immunodeficiency disorders (on account of macrophages) or catch and move of virions in trans (on account of dendritic cells)

Mechanism of Diabetes Mellitus

Diabetes mellitus is certifiably not a solitary issue, it addresses a progression of metabolic conditions related to hyperglycemia and brought about by absconds in insulin emission and additionally insulin activity. Openness to constant hyperglycemia may result in microvascular entanglements in the retina, kidney, or periphery (28–30). The blood conveys glucose to furnish the body with energy to play out the entirety of an individual's day-by-day exercises. The liver converts the food an individual eats into glucose. The glucose is then delivered into the circulatory system. In a solid individual, the blood glucose level is managed by a few chemicals, principally insulin. Insulin is delivered by the pancreas, a little organ between the stomach and liver (31). The pancreas additionally makes other significant catalysts delivered straightforwardly into the gut that helps digest food. Insulin permits glucose to move out of the blood into cells all through the body where it is utilized for fuel (32). Individuals enduring diabetes either don't create sufficient insulin (type 1 diabetes) or can't utilize insulin appropriately (type 2 diabetes) (33,34), or both (which happens with a few types of diabetes). In diabetes, glucose in the blood can't move proficiently into cells, so blood glucose levels stay high. This not just starves all the cells that require the glucose for fuel, yet additionally hurts certain organs and tissues presented to the high glucose levels (35).

Mechanism of Anemia

Around 33% of the 5.5 billion individuals on the planet are anemic. hemoglobin under 11 g/dL for kids aged under 4 and pregnant ladies, hemoglobin under 12 g/dL for children 5 to 12 years and nonpregnant ladies, and hemoglobin under 13 g/dL for men are known to be anemic(36). The type of mechanism in which anemia is caused is due to the Dysregulation of the inflammatory response, Blunting of hypoxia/erythropoietin sensing mechanism, Sarcopenia, Quantitative/qualitative alterations in stem cell physiology, Decrease in sex steroids, Frequent co-morbid medical conditions, and polypharmacy (37).

Mechanism of chemotherapy-induced immunodeficiency

The utilization in the clinical medication of chemotherapeutic specialists with immunosuppressive action is aimed at mitigating immunologically interceded sickness, lymphoproliferative illnesses, and anticipation of uniting dismissals following organ transplantation(38).

A complex group of disorders that result from defects in immune system development or function. They are present in both children and adults, and although signs and symptoms are

highly variable, most disorders involve increased susceptibility to infection, with many leading to significant disease-associated morbidity and mortality. Other important signs include excessive inflammatory responses and autoimmunity. The nature of these conditions requires referral to an immunologist for proper diagnosis and care. Severe diseases, such as HIV, necessitate long-term immune therapy. (e.g., BMT, HSCT, gene therapy) as soon as possible, which has led to the application of newborn screening to this population. B-cell or antibody-deficiency disorders are the most common types. The mainstay of treatment for patients with these disorders is immunoglobulin replacement therapy, and there are now several Ig products approved around the world for patients with immunodeficiency.

Our team has extensive knowledge and research experience that has translate into high quality publications (7).(8–19,39,40) ,(20,21,41–43)

Conclusion:

This review highlighted the pathogenic mechanism of immunodeficiency in various systemic immunodeficiency disorders like HIV, Anemia, Diabetes Mellitus, Chemotherapy related immunodeficiencies. This review emphasizes that all the common systemic immunodeficiency disorders must be taken into a consideration in treatment in clinical practice.

Table 1: Comparison of literature in relation to common systematic immunodeficiency disorders

LITERATURE COMPARISON	RELATION TO COMMON SYSTEMIC IMMUNODEFICIENCY DISORDERS	DEPENDENT VARIABLE
. <i>Abbott, J K et al.,</i>	+++	gene deletion
<i>Chan et al.,</i>	++	viral envelope, HIV capsid
<i>CunninghamRundles, C.et al.,</i>	+++	immune disorder
<i>Ezekowitz, J.A.et al.,</i>	+	dysregulation of inflammatory response
<i>Freed, E.O.et al.,</i>	++	contaminated lymphocyte, immune system microorganism
<i>Gillespie, K.M. et al.,</i>	+	insulin, pancreas
<i>Jolly, C.et al.,</i>	nil	direct transmission, cell to cell spread
<i>Lehman, H.K. et al.,</i>	+	B cells, T cells

Mogensen, T.H et al.,	+++	platelets, glucose level
<i>Narendran, P. et al.,</i>	++	gut,glucose
Notarangelo, et al.,	++	secondary immunodeficiency
Ohmoto A et al.,	+++	immunosuppressive action
Pac M et al.,	+	primary immunodeficiency
<i>Rasmussen, L.et al.,</i>	++	hemoglobin
Resnick, E.S. et al.,	+++	immunoglobulin replacement therapy
Stumvoll,M. Et al.,	+	insufficient insulin
Thivolet, C.et al.,	++	metabolic conditions, insulin emission
Wellen, K.et al.,	+	high blood glucose level
Wyatt, R. et al.,	+++	target cell

Acknowledgements

We would like to thank Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University for providing us support to conduct the study.

Conflict of interest

The author declares that there were no conflicts of interests in the present study.

Source of funding

The present project is supported by

- Saveetha Institute of Medical and Technical Sciences
- Saveetha Dental College and Hospitals, Saveetha University
- Jeevan clinic

Reference

1. Cunningham-Rundles C. Common variable immune deficiency: case studies [Internet]. Vol. 2019, Hematology. 2019. p. 449–56. Available from: <http://dx.doi.org/10.1182/hematology.2019002062>
2. Pac M, Bernatowska E. Comprehensive activities to increase recognition of primary immunodeficiency and access to immunoglobulin replacement therapy in Poland. *Eur J Pediatr.* 2016 Aug;175(8):1099–105.
3. Notarangelo LD, Fischer A, Geha RS, Casanova J-L, Chapel H, Conley ME, et al. Primary immunodeficiencies: 2009 update [Internet]. Vol. 124, *Journal of Allergy and Clinical Immunology.* 2009. p. 1161–78. Available from: <http://dx.doi.org/10.1016/j.jaci.2009.10.013>
4. Abbott JK, Gelfand EW. Common Variable Immunodeficiency: Diagnosis, Management, and Treatment. *Immunol Allergy Clin North Am.* 2015 Nov;35(4):637–58.
5. Resnick ES, Cunningham-Rundles C. The many faces of the clinical picture of common variable immune deficiency [Internet]. Vol. 12, *Current Opinion in Allergy & Clinical Immunology.* 2012. p. 595–601. Available from: <http://dx.doi.org/10.1097/aci.0b013e32835914b9>
6. Harsha L, Brundha MP. Prevalence of Dental Developmental Anomalies among Men and Women and its Psychological Effect in a Given Population. *Journal of Pharmaceutical Sciences and Research; Cuddalore.* 2017 Jun 20;9(6):869–73.
7. Anita R, Paramasivam A, Priyadharsini JV, Chitra S. The m6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients. *Am J Cancer Res.* 2020 Aug 1;10(8):2546–54.
8. Jayaseelan VP, Paramasivam A. Emerging role of NET inhibitors in cardiovascular diseases. *Hypertens Res.* 2020 Dec;43(12):1459–61.
9. Sivakumar S, SmilineGirija AS, VijayashreePriyadharsini J. Evaluation of the inhibitory effect of caffeic acid and gallic acid on tetR and tetM efflux pumps mediating tetracycline resistance in *Streptococcus* sp., using computational approach. *Journal of King Saud University - Science.* 2020 Jan 1;32(1):904–9.
10. SmilineGirija AS. Delineating the Immuno-Dominant Antigenic Vaccine Peptides Against gacS-Sensor Kinase in *Acinetobacter baumannii*: An in silico Investigational Approach. *Front Microbiol.* 2020 Sep 8;11:2078.
11. IswaryaJaisankar A, SmilineGirija AS, Gunasekaran S, VijayashreePriyadharsini J. Molecular characterisation of csgA gene among ESBL strains of *A. baumannii* and targeting with essential oil compounds from *Azadirachta indica*. *Journal of King Saud University - Science.* 2020 Dec 1;32(8):3380–7.
12. Jayaseelan VP, Ramesh A, Arumugam P. Breast cancer and DDT: putative interactions, associated gene alterations, and molecular pathways. *Environ Sci Pollut Res Int.* 2021 Jun;28(21):27162–73.

13. Arumugam P, George R, Jayaseelan VP. Aberrations of m6A regulators are associated with tumorigenesis and metastasis in head and neck squamous cell carcinoma. *Arch Oral Biol.* 2021 Feb;122:105030.
14. Kumar SP, Girija ASS, Priyadharsini JV. Targeting NM23-H1-mediated inhibition of tumour metastasis in viral hepatitis with bioactive compounds from *Ganoderma lucidum*: A computational study. *pharmaceutical-sciences* [Internet]. 2020;82(2). Available from: <https://www.ijpsonline.com/articles/targeting-nm23h1mediated-inhibition-of-tumour-metastasis-in-viral-hepatitis-with-bioactive-compounds-from-ganoderma-lucidum-a-comp-3883.html>
15. Girija SA, Priyadharsini JV, Paramasivam A. Prevalence of carbapenem-hydrolyzing OXA-type β -lactamases among *Acinetobacter baumannii* in patients with severe urinary tract infection. *Acta Microbiol Immunol Hung.* 2019 Dec 9;67(1):49–55.
16. Priyadharsini JV, Paramasivam A. RNA editors: key regulators of viral response in cancer patients. *Epigenomics.* 2021 Feb;13(3):165–7.
17. Mathivadani V, Smiline AS, Priyadharsini JV. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA-1) with *Murrayakoengii* bio-compounds: An in-silico approach. *Acta Virol.* 2020;64(1):93–9.
18. Girija As S, Priyadharsini J V, A P. Prevalence of Acb and non-Acb complex in elderly population with urinary tract infection (UTI). *Acta Clin Belg.* 2021 Apr;76(2):106–12.
19. Anchana SR, Girija SAS, Gunasekaran S, Priyadharsini VJ. Detection of *csgA* gene in carbapenem-resistant *Acinetobacter baumannii* strains and targeting with *Ocimum sanctum* biocompounds. *Iran J Basic Med Sci.* 2021 May;24(5):690–8.
20. Varghese SS, Ramesh A, Veeraiyan DN. Blended Module-Based Teaching in Biostatistics and Research Methodology: A Retrospective Study with Postgraduate Dental Students. *J Dent Educ.* 2019 Apr;83(4):445–50.
21. Mathew MG, Samuel SR, Soni AJ, Roopa KB. Evaluation of adhesion of *Streptococcus mutans*, plaque accumulation on zirconia and stainless steel crowns, and surrounding gingival inflammation in primary molars: randomized controlled trial [Internet]. Vol. 24, *Clinical Oral Investigations*. 2020. p. 3275–80. Available from: <http://dx.doi.org/10.1007/s00784-020-03204-9>
22. Mogensen TH. Primary Immunodeficiencies with Elevated IgE. *Int Rev Immunol.* 2016;35(1):39–56.
23. Lehman HK. Autoimmunity and Immune Dysregulation in Primary Immune Deficiency Disorders. *Curr Allergy Asthma Rep.* 2015 Sep;15(9):53.
24. Chan DC, Kim PS. HIV entry and its inhibition. *Cell.* 1998 May 29;93(5):681–4.
25. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. *Science.* 1998 Jun 19;280(5371):1884–8.
26. Freed EO. *Advances in HIV-1 Assembly and Release.* Springer Science & Business Media; 2013. 221 p.

27. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. *J Exp Med*. 2004 Jan 19;199(2):283–93.
28. Thivolet C, Vial G, Cassel R, Rieusset J, Madec A-M. Reduction of endoplasmic reticulum-mitochondria interactions in beta cells from patients with type 2 diabetes [Internet]. Vol. 12, *PLOS ONE*. 2017. p. e0182027. Available from: <http://dx.doi.org/10.1371/journal.pone.0182027>
29. Hannah R, Ramani P, Brundha MP, Sherlin HJ, Ranjith G, Ramasubramanian A, et al. Liquid Paraffin as a Rehydrant for Air Dried Buccal Smear. *Research Journal of Pharmacy and Technology*. 2019;12(3):1197–200.
30. Timothy CN, Samyuktha PS, Brundha MP. Dental pulp Stem Cells in Regenerative Medicine--A Literature Review. *Research Journal of Pharmacy and Technology*. 2019;12(8):4052–6.
31. Gillespie KM. Type 1 diabetes: pathogenesis and prevention. *CMAJ*. 2006 Jul 18;175(2):165–70.
32. Narendran P, Estella E, Furlanos S. Immunology of type 1 diabetes. *QJM*. 2005 Aug;98(8):547–56.
33. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. *Lancet*. 2005;365(9467):1333–46.
34. Preethikaa S, Brundha MP. Awareness of diabetes mellitus among general population. *Research Journal of Pharmacy and Technology*. 2018;11(5):1825–9.
35. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. *J Clin Invest*. 2005 May;115(5):1111–9.
36. Rasmussen L, Arvin A. Chemotherapy-induced immunosuppression [Internet]. Vol. 43, *Environmental Health Perspectives*. 1982. p. 21–5. Available from: <http://dx.doi.org/10.1289/ehp.824321>
37. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. *Circulation*. 2003 Jan 21;107(2):223–5.
38. Ohmoto A, Fuji S. Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders. *Blood Rev*. 2021 Feb 6;100807.
39. Giriya ASS. Fox3+ CD25+ CD4+ T-regulatory cells may transform the nCoV's final destiny to CNS! *J Med Virol* [Internet]. 2020 Sep 3; Available from: <http://dx.doi.org/10.1002/jmv.26482>
40. Giriya ASS, Shoba G, Priyadharsini JV. Accessing the T-Cell and B-Cell Immuno-Dominant Peptides from *A.baumannii* Biofilm Associated Protein (bap) as Vaccine Candidates: A Computational Approach. *Int J Pept Res Ther*. 2021 Mar 1;27(1):37–45.

41. Arvind P TR, Jain RK. Skeletally anchored forsus fatigue resistant device for correction of Class II malocclusions-A systematic review and meta-analysis. *OrthodCraniofac Res.* 2021 Feb;24(1):52–61.
42. Venugopal A, Vaid N, Bowman SJ. Outstanding, yet redundant? After all, you may be another Choluteca Bridge! *Semin Orthod.* 2021 Mar 1;27(1):53–6.
43. Ramadurai N, Gurunathan D, Samuel AV, Subramanian E, Rodrigues SJL. Effectiveness of 2% Articaine as an anesthetic agent in children: randomized controlled trial. *Clin Oral Investig.* 2019 Sep;23(9):3543–50.

UNDR PEER REVIEW